Efeito otoprotetor da oxigenoterapia hiperbárica na toxicidade causada pela cisplatina by YASSUDA, Camila C. et al.
Yassuda CC et al
72 - Acta Cirúrgica Brasileira - Vol 23 (Supplement 1) 2008
1.   Study performed in the Department Otorhinolaryngology, University Hospital, Ribeirão Preto Faculty of Medicine, University of São
Paulo. Brazil
13-EXPERIMENTAL RESEARCH
ORIGINAL ARTICLE
Effects of Drugs
The role of hyperbaric oxygen therapy (hot) as an otoprotection agent against
cisplatin ototoxicity1
Efeito otoprotetor da oxigenoterapia hiperbárica na toxicidade causada pela cisplatina
Camila C. YassudaI, Ana Elisa M. RighettiII, Maria Cristina L. CuryIII, Miguel Ângelo HyppolitoIV, José Antonio A. de
OliveiraV, Omar FéresVI
I MD, Resident in Otorhinolaryngology, Ribeirao Preto Faculty of Medicine,  University of São Paulo, Brazil.
II Graduate Student of the Ribeirao Preto Faculty of Medicine, University of São Paulo, Brazil.
III PhD, Professor, Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Faculty of Medicine,
University of  São Paulo, Brazil.
IV PhD, Professor, Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Faculty of Medicine,
University of  São Paulo, Brazil.
V Full Professor, Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Faculty of Medicine,
University of  São Paulo, Brazil.
VI PhD, Professor, Division of Coloproctology,  Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of
São Paulo, Brazil.
ABSTRACT
Purpose: Hyperbaric oxygen therapy (HOT) consists of intermittent inhalations of 100% oxygen at a pressure higher than
1 atm. It is an important adjuvant therapy in pathological processes like soft tissue infections, radiation injury, gas
gangrene, osteomyelitis and decompressive diseases.  Cisplatin, a potent antineoplastic drug, widely used in cancer
therapy is highly ototoxic causing bilateral, irreversible damage to the hearing of high frequency sounds (4-8 KHz).
Objective:This experimental study conducted at the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo aims
to evaluate Hyperbaric Oxygen Therapy as an otoprotection agent against drug toxicity. Methods: Albino guinea pigs
were divided into two groups: in Group A, 5 animals (10 cochlea) received cisplatin, i. p., 8.0 mg/kg/day during three days
and afterwards were submitted to HOT; in Group B, 3 animals (6cochlea) received cisplatin, i. p. 8.0mg/kg/day during three
days. Guinea pigs were evaluated by acoustic otoemissions (AOE) and scanning electron microscopy (SEM). Results:
Group B animals showed loss of auditory functions as measured by AOE and distorted outer hair cells by SEM. In Group
A, outer hair cells shown by SEM images were mostly preserved. Conclusion: It is presumed that Hyperbaric Oxygen
Therapy has a protector effect against cisplatin ototoxicity.
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RESUMO
Introdução: A Oxigenoterapia hiperbárica (OHB) envolve a inalação de oxigênio a 100% sob uma pressão maior que 1 atm.
E um importante modo de terapia adjuvante para processos patológicos,  tais como: infecção de partes moles, lesões
actínicas, gangrena gasosa,  osteomielite e doença descompressiva. A cisplatina e uma potente droga antineoplásica
largamente utilizada para o tratamento de câncer. A ototoxicidade e um importante efeito colateral desta droga, causando
dano irreversível, bilateral, na capacidade de ouvir sons de alta freqüência (4 - 8 KHz). Este estudo experimental, realizado
na Faculdade de Medicina de Ribeirao Preto da Universidade de São Paulo nos anos de 2005 e 2006. Objetivo: Avaliar o
papel da Oxigenoterapia Hiperbárica como agente otoprotector contra a toxicidade de drogas. Métodos: Cobaias albinas
divididas em 2 grupos Grupo A: com 5 cobaias (10 cócleas) que receberam cisplatina 8,0 mg/kg/dia, via intraperitoneal por
3 dias, submetidas posteriormente a OHB. Grupo B: com 3 cobaias (6 cócleas) que receberam cisplatina 8,0 mg/kg/dia, via
intraperitoneal por 3 dias. As cobaias foram avaliadas através de otoemissões acústicas (OEA) e por microscopia eletrônica
de varredura (MEV). Resultados: Encontramos no grupo B perda da função auditiva medida pela OEA e distorção das
células ciliares externas a MEV. No grupo A, a MEV as células ciliares externas foram preservadas em sua grande maioria.
Conclusão: Assim podemos supor que a Oxigenoterapia Hiperbárica tem um efeito otoprotetor contra a ototoxicidade
induzida pela cisplatina.
Descritores: Oxigenoterapia Hiperbárica. Ototoxicidade. Otoprotecão. Cisplatina.
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Introduction
The organ of Corti is the fundamental neuro-sensorial
structure in the peripheral auditive processing of the
acoustic message. It consists of complex epithelial
structures, with sensorial and supporting cells resting on
the basilar membrane. The sensorial cells are of two types,
outer and inner hair cells. Ototoxicosis are iatrogenic
affections produced by therapeutic drugs on the inner ear.
The drugs affect both the cochlear and / or the vestibular
systems, causing transitory or permanent injury. Cisplatin,
a potent antineoplastic drug, widely used in cancer therapy
in adults and children shows ototoxicity as its main collateral
effect, which limits therapeutic application.1
Cisplatin ototoxicity is clinically characterized by
bilateral irreversible hearing detection of high frequency
sounds with associated tinnitus.2-6  It is known that cisplatin
ototoxicity is related to alterations in the anti-oxidant
mechanisms in hair cells and several studies show that a
major and dose dependent lesion is caused by cisplatin on
outer cochlear hair cells, specially those at the spiral lamina
responsible for transduction of high frequency sounds.
Anatomical studies of the inner ear indicate that
damage may be equally produced by high cisplatin dosages
or cumulative ones. The possible lesion producing
mechanisms include calcium channel blockades in outer hair
cells, supporting cells, stria vascularis as well as in the spiral
ganglion.7-13
The last decade has seen studies aiming at a better
understanding of the anti-oxidant mechanisms of outer hair
cells, compromised by ototoxic drugs like aminoglycosides
and cisplatin. Several potential oto protective drugs, which
act blocking  lesion producing mechanisms to the anti-
oxidant system of the outer hair cells have been tested.
Drugs like fosfomycin, sulfur compounds, sodium
thiosulfate, diethyl carbamate, adrenocorticotropic hormone
(ACTH) and derivatives, 4-methylthiobenzoic acid, lipoic
acid, glutathione and esters, metionine, alpha-melanocytic
stimulating hormone (melatonin) and anti-oxidants like
ginkgo biloba extracts, all anti-free radicals, were effectively
tested.11,14-20
Hyperbaric oxygen therapy (HOT), having an
important anti-oxidant activity is being increasingly used
and it is based on inhalation of 100% oxygen under
pressures above 1 atm. It is precisely indicated as a stimulant
of wound healing and cellular growth.
In Brazil, the Federal Medical Council regulated HOT
therapeutic use through Resolution CFM 1457/95
summarized as follows:   gas embolism;   decompressive
disease;   traumatic air embolism; gas gangrene; Fournier´s
syndrome; necrotic infections of soft tissues (cellulitis,
fasciitis and myositis); allergic, drug or biologic toxins
(Arachnida,Ophidia and Insecta) originated acute vasculitis;
radiation lesions (radiation dermatitis, osteoradionecrosis
and mucosal actinic lesions); acute anemia in cases where
blood transfusions are not possible; acute traumatic
ischemia (crushing lesions, compartment syndrome,
reimplantation of amputated extremities); thermal or electric
burns; refractory lesions like skin ulcers (diabetic foot,
decubital scars, autoimmunee vasculitis ulcers, suture
dehiscences) and compromised repairs or grafts.
Mechanical pressure effects and increased tissue
oxigenation are the two active factors related to the
hyperbaric environment in HOT, The physiological and
pharmacological effects of high oxygen dosages are not
completely known. It seems that the main effect is tissue
hyperoxigenation (increased pO2) through plasma
dissolved oxygen. Diffusion of the gas though skin or
wounds is not significant. Increased bacterial fagocytosis
by polymorphonucleates (PMN) has been observed during
hyperoxygenation, as well as increased production of
fibroblasts and proliferation of bone cells.21
An experimental study by Zamboni22 demonstrated
that angiogenesis stimulation is directly related to the
oxygen gradient in wounds.
The possible deleterious effects of excessive “free
radicals” (RES, reactive oxygen species) were not verified
experimentally. In contrast, anti-oxidant effects were
observed though decreased neutrophil adhesion22 and NO
increase, which may combine with superoxide anions
blocking their effects.23 In rat experimental pancreatitis, HOT
not only improved the pancreatic lesion but elevated the
levels of superoxide dismutase (SOD) metabolizing the
oxidative radicals.24
Objective
The study aims to evaluate the role of Hyperbaric
Oxygen Therapy (HOT) as a protective agent against drug
toxicity. Cisplatin, an efficient currently used ototoxic agent
was selected as the experimental model drug.
Methods
Albino guinea pigs, the chosen experimental animals
are easily handled, allow adequate cochlear dissection and
manipulation and the i.p., intramuscular or sub-cutaneous
infusion of anesthetics and experimental drugs is facilitated.
The 8 adult albino guinea pigs weighing around 360-590 g
and raised at the Central Animal House of the University of
São Paulo- Ribeirão Preto Campus were selected through
the Preyer reflex,25 kept during the experimental period at
the Laboratory of Experimental Surgical Techniques, Faculty
of Medicine of Ribeirão Preto, University of São Paulo, and
checked every day for weight control. Animal handling and
procedures were according to the guidelines of the Institute
of Laboratory Animal Resources, Commission of Life
Sciences, National Research Council, National Academy
Press, Washington, D.C. 1996. This project was submitted
and approved on the Ethics in Research Committee of
FMRP-USP.
All animals were submitted to the exam of distortion
product otoacoustic emissions (DPOAE) in an acoustic
chamber, under anesthesia with intramuscular cetamin
hydrochloride, 10mg/kg and xylazin, 4mg/kg. The device
used was the ILO 92 CAE System Otodynamics Ltd., with
the frequency relation 2F1-F2 and the ratio F1/F2=1.22. The
inclusion criterion in this study was an initial otoacoustic
exam showing normal responses, which reveal outer hair
cells integrity.
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Intra peritoneal administration of cisplatin
(CisplatexÒ) was accompanied by hydration with 10ml
physiological saline. The two cochlea of each guinea pig
were used, since cisplatin is a systemic acting drug.
Guinea pigs were divided into two groups, A,
containing 5 animals (10 cochlea) receiving 8.0 mg/kg/day,
i.p. for three days and B, with 3 animals (6 cochlea) treated
in the same way as A. The choice of the cisplatin dosage
was based on literature reports, which show production of
significant cellular lesions, with anatomical alterations
verified by SEM and functional ones by otoacoustic
emissions.26
One day after final drug administration all animals
were tested by otoacoustic emission, and the animals of
group B euthanized in the same day. Group A guinea pigs,
kept in propylene cages, were treated by Hyperbaric Oxygen
Therapy, during 60 minutes at 2 ATA, on the 6o, 8o and 10o
day after the start of cisplatin administration and checked
by otoacoustic emissions following each hyperbaric
treatment.
Hyperbaric therapy was applied in a experimental
chamber directly pressurized by oxygen and located at the
Experimental Surgery Sector of the Department of Surgery
and Anatomy, FMRP-USP.
For cochlear anatomical evaluation, guinea pigs were
anesthetized by ether inhalation, decapitated and the bula
containing temporal bones removed. Bula openings at the
cochlear apex and round window were filled for fixation
with 2.5% glutaraldehyde in 0.1M phosphate buffer
(Sorensen) at 4oC. The micro dissection preserved the spires
and the material was kept for 12 hours in 0.1M buffer
solution, and fixed again in 1% osmium tetroxide in
phosphate buffer for one hour at 4oC.  Following
dehydration by ethanol the material was dried by the critical
point method with liquid CO2 in a BALTEC-CPD- “Critical
Point Dryer”.
Cochlea positioned on a cylindrical specimen support
with a carbon conducting paste received a fine gold layer
dispensed by a BALTEC SDC050 vaporizer and analyzed
by SEM (JOEL JMS-5200). Representative samples of the
medial third of each cochlea spiral lamina, containing 120
outer hair cells in three rows of 40 cells and 40 inner hair
cells, were photographed and evaluated.    In each field, hair
cell counts were made at the medial third of the basal spires,
second spire (E2), third spire (E3) and the cochlear basal
spire, three rows of 40 cells, present or absent being counted.
The cochlear apical section was not considered in this
study, since normal cochlea already show a pattern of cellular
disarrangement.
Results
The results in this study are based on the analysis
of cochlea morphology (SEM of basal spire) and function
by otoacoustic emissions (OAE). Thus, in guinea pigs of
control group B the auditory function was lost in 2 of the 3
animals as  measured by OAE, and outer hair cells showed
distortions in the cochlea basal spire after cisplatin treatment,
confirming other reports showing ototoxicity when the drug
dosage was applied for the same time period (Figure1).
Animals in group A, treated by hyperbaric oxygen therapy,
but previously submitted to the same dosage of cisplatin,
showed outer hair cells mostly preserved (Figure 2) but
distortion product otoacoustic emissions were absent in all
animals.
Discussion
Confirming observations by Cardinaal et al.12, this
study showed that cisplatin induces dose-dependent
cochlear alterations.  High drug dosages in short periods of
time (8mg/kg/day, three days) led to cellular lesions and
significant hair damage in outer hair cells. By choosing this
dosage, it was certain that lesions would be found in more
than 65% of the outer cells in the basal spire as well as
evident functional alterations. SEM and PDOAE evaluated
the anatomical and functional alterations, respectively.
PDOAE, a simple method representing the cell functional
state, was employed in this study, since it is known that
otoacoustic emissions evaluate the state of contraction in
outer cells.
Until recently most studies about cisplatin
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ototoxicity evaluated cochlea functional alterations through
action potential, somation potential and cochlear
microphonics or through Brainstem Evoked Auditory
Potentials (BAEP). Sokalingam et al. (2000)13 verified that
transient and distortion product registered otoemissions
are a sensitive method to evaluate the functional status of
outer hair cells and that the albino guinea pig is a sensitive
animal. In terms of ototoxicity to cisplatin, at dosages of 8-
12 mg/kg/day, in three days the animals show DPOAE
alterations and lesioned outer hair cells, with amplitude
depressions in the distortion product greater than in
transient OAEs.
The literature shows several compounds being
tested for protection against cisplatin ototoxicity, such as:
diethylcarbamate, 4-methylthiobenzoic acid, ebselen,
melatonin, lipoic acid, acetyl cysteine, phosphomycin,
neurothrophins, ACTH analogs11,14-19. Several of these drugs
have in vivo collateral effects and little is known about a
possible interference action on the anti-neoplastic activity
of cisplatin.
Analysis of the number of cochlear outer hair cells
and their anatomical alterations showing hair losses and
distortions indicated signs of otoprotection in Group A
animals treated with Hyperbaric Oxygen Therapy. There
were statistically significant differences when compared to
Group B treated in the same way with cisplatin only.
However, in functional studies, DPOAEs were absent
reflecting a loss of hearing, which may be reversible and
possible related to the presence of secretion and
hemorrhagic signs during bula dissection to remove the
cochlea.
The high death rate in this experimental model, 8.0
mg/kg/day during three days is significant considering that
only 3 animals in Group A survived until the end of the HOT
cycles.
Concomitant use of cisplatin and Hyperbaric
Oxygen Therapy is contra-indicated but in this case cisplatin
was used as an efficient lesion producer in cochlea outer
hair cells in a short time12 and the hyperbaric therapy only
started 48 hours after the last drug dose.
Several studies on cisplatin oto and nephrotoxicity
point to alterations in cell anti-oxidant potentials. It was
shown that levels of glutathione (GSH) and antioxidant
enzymes as superoxide dismutase (SOD), catalase, GSH
peroxidase and GSH reductase are reduced in these tissues
leading to lipid peroxidation, thus, to cellular toxicity.3,12,15,17,18
Anti-oxidant effects of Hyperbaric Oxygen Therapy
have been observed through decrease in neutrophils
adhesion22 and increased  NO production, which combine
with superoxide anions blocking their effects.23 In
experimental pancreatitis in rats, it was demonstrated that
HOT promotes an elevation in levels of super oxide
dismutase (SOD) with metabolization of oxidant radicals.24
Hyperbaric oxygen use as a therapeutic method has
been progressively used and increasingly present in
scientific studies. Its possible otoprotector effects should
be valorized and it could become a valuable therapeutic
tool. However, other effects of high pressure oxygen on the
cochlea should be considered in further studies.
Conclusion
Based on the results in this study it is possible to
conclude that Hyperbaric Oxygen Therapy has an
otoprotector effect against cisplatin -induced ototoxicity.
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Comments:
Ototoxicity has been a significant problem with cisplatin, a potent antineoplastic drug. The hearing loss is usually in the
high-frequency range but may occur in the lower ranges, which include the speech frequencies. Because the higher
frequencies are usually involved, the hearing loss may not be symptomatic. The ototoxicity of cisplatin is dose related and
is usually cumulative. The pathologic findings associated with cisplatin are selective damage to the outer hair cells of the
cochlea and lesions in the organ of Corti, the spiral ganglion and cochlear nerve, and the stria vascularis. Probably an
alteration in cell anti-oxidant potential might be present, leading to lipid peroxidation and cellular toxicity. Hyperbaric
oxygen therapy, that consists on inhalation of 100 percent oxygen inside a   hyperbaric chamber, with its anti-oxidant
effect, has the potential of otoprotection against cisplatin. This was the conclusion of this well-conducted study. We must
remember that hyperbaric oxygen also reverses local hypoxia, inhibits postischemic vasoconstriction, and promotes the
formation of collagen matrix, which is essential for angiogenesis and restoration of blood flow to the injured tissue.
However, the death rate on the experiment was high, what means that we need further studies to confirm the utility of this
therapy.
Wilson Salgado Filho
MD, PhD,  Department of Surgery and Anatomy, Ribeirão Preto Faculty of Medicine, University of São Paulo, Brazil.
